Evaluation of Serum Apelin in Acute Coronary Syndrome Patients
Background: Acute coronary syndrome refers to any group of clinical symptoms compatible with acute myocardial ischemia including unstable angina (UA), Non-ST-segment elevation myocardial infarction (NSTEMI) & ST-segment elevation myocardial infarction (STEMI).
Apelin is a novel endogenous peptide with inotropic and vasodilatory properties, it was recently reported that serum measurements of apelin were similar to its immunohistochemical data in vessels and heart tissues.
Objectives: This study aims to evaluate serum levels of apelin in patients with Acute Coronary Syndrome related to severity of presentation.
Patients and Methods: The present study was conducted during the period from September 2014 until March 2015. Fifty-nine patients with ACS were included as (30 UA, 15 NSTEMI, & 14 STEMI) patients. Also the study included (28) apparently healthy persons served as control. Blood samples were obtained for measurements of Apelin by ELISA method.
Results: Serum apelin levels were significantly decreased in whole group of patients with ACS (1846.1±320.9) ng/ml compared to control (2719.4±272.5) ng/ml (p< 0.05). Regarding patients’ subgroups; serum apelin was lowest in STEMI (1729.0±480.0) ng/ml, NSTEMI (1816.0±289.0) ng/ml, & UA (1916.0±224.4) ng/ml when compared with control; respectively.
Conclusion: Data obtained revealed a reduction in serum apelin levels in all patients groups especially STEMI, so it could be considered as a biochemical marker for evaluation of ACS.
For all articles published in Journal of the Faculty of Medicine Baghdad, copyright is retained by the authors. Articles are licensed under an open access Creative Commons CC BY NC 4.0 license, meaning that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. These conditions allow for maximum use and exposure of the work, while ensuring that the authors receive proper rights.